ALLMedicine™ Paroxysmal Supraventricular Tachycardia Center

Mar 30th, 2022 - MicroRNAs (miRNAs) are small non‑coding RNAs that control patterns of gene expression by inducing the degradation of mRNAs. In addition, miRNAs are known to serve an important role in the pathogenesis of atrial fibrillation (AF). In general, AF is...

Feb 12th, 2022 - International guidelines define as paroxysmal supraventricular tachycardia (PSVT) all supraventricular tachyarrhythmias other than atrial flutter and atrial fibrillation. Associate symptoms, such as chest pain and dyspnea, and possible ECG changes...

Jan 28th, 2022 - Intravenous adenosine is the recommended treatment for paroxysmal supraventricular tachycardia (PSVT). There is no official recommended method of giving adenosine. We compared the success rates between a standard and alternative method of first do...

Nov 19th, 2021 - The Singapore Cardiac Databank was designed to monitor the performance and outcomes of catheter ablation. We investigated the outcomes of paroxysmal supraventricular tachycardia (PSVT)-ablation in a prospective, nationwide, cohort study. Atriovent...

Sep 16th, 2021 - Heart diseases are the leading causes of mortality and Congenital Heart Disease (CHD) is the most common birth defect reported worldwide. The aim of this study was to evaluate the incidence of arrhythmias and CHD and the association between the tw...

Dec 30th, 2020 - This is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the effects of 4 different doses of MSP-2017 (Etripamil) in subjects with paroxysmal supraventricular tachycardia. It includes an up to 21-day Scr...

Mar 18th, 2020 - A total of 100 patients with persistent，in whom successful RF ablation of slow pathway or accessory pathway was performed. Patients with atrial fibrillation, structural heart disease, ventricular arrhythmias, impaired left ventricular systolic fu...

Jul 29th, 2016 - OUTLINE: This is a multi-center study. Pemetrexed 500mg/m2 will be administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle. Folic Acid (350-1000 mcg. PO daily) will be taken by patients to reduce toxicity. At least 5 da...

Mar 14th, 2016 - OUTLINE: This is a multi-center study. Cisplatin 70 mg/m2 Day 1 Gemcitabine 1250 mg/m2 Day 1 and 8 Bevacizumab 15 mg/kg Day 1 Review toxicity every cycle (every 3 weeks) Review for radiographic response every 2 cycles (every six weeks) Progressive...

May 11th, 2022 - A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular tachycardia (PSVT), has advanced another step i...

May 16th, 2021 - Significant improvement in the control of symptoms related to paroxysmal supraventricular tachycardia (PSVT) is resurrecting etripamil as a self-administered nasal spray a year after it failed to meet the primary endpoint in a phase 3 trial, accor...

Aug 1st, 2018 - THE CASE A 29-year-old G1P0 woman at 13 weeks’ gestation came in for a routine prenatal visit complaining of sudden-onset heart palpitations that were occurring about once a week. Each episode lasted between 15 and 60 minutes and was accompanied b.

Jul 24th, 2018 - Self-treatment of acute paroxysmal supraventricular tachycardia (SVT) with a nasal spray containing a short-acting calcium-channel blocker is likely to be possible with a high rate of conversion to sinus rhythm, suggests a phase 2 study. The nasal...

May 16th, 2017 - CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data from the Intranasal Etripamil for the Conversion o...